QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
🧠Quantifying burden across borders: Japanese Encephalitis in APAC
At today’s ISPOR Real-World Evidence Summit 2025 , Puneet Kaushik presented new insights into the economic burden of Japanese Encephalitis(JE) across Asia-Pacific.
🔍 Despite vaccines and treatments, JE continues to strain health systems through:
• High inpatient and ICU demands
• Significant productivity losses—up to 860 workdays per case
• Wide cost variability: from $106 to $1,644 per case across countries
This systematic review drew from real-world data in China, Bangladesh, Indonesia, the Philippines and […]
Off to Tokyo: Real-world evidence through an APAC lens
Quantify’s Puneet Kaushik is heading to the ISPOR Real-World Evidence Summit 2025 in Tokyo.
He’ll be presenting new findings on:
🧠 RWD317: The Burden of Japanese Encephalitis in Asia-Pacific
📅 𝘗𝘰𝘴𝘵𝘦𝘳 𝘚𝘦𝘴𝘴𝘪𝘰𝘯 2
📍 𝘗𝘰𝘴𝘵𝘦𝘳 𝘉𝘰𝘢𝘳𝘥 4018
🕒 𝘛𝘶𝘦𝘴𝘥𝘢𝘺, 30 𝘚𝘦𝘱𝘵𝘦𝘮𝘣𝘦𝘳, 13:00–14:00 (𝘋𝘪𝘴𝘤𝘶𝘴𝘴𝘪𝘰𝘯 𝘱𝘦𝘳𝘪𝘰𝘥)
If you’re attending, don’t miss the chance to connect with Puneet. He’s keen to exchange thoughts on:
• Evidence Review & Synthesis 🔍
• Medical Writing & Editorial Services ✍
• Real-World Evidence Applications […]
🧬Sex differences, EBV & MS: new insights from Nordic RWE
ECTRIMS kicks off today in Barcelona—the world’s largest multiple sclerosis conference.
Quantify is proud to contribute to two posters this year:
📍 P628 – Kelsi Smith (Quantify) presents her PhD research on sex differences in the genetic association between MC1R and MS risk.
📍 P068 – Moderna presents a Danish-Swedish observational study on MS risk linked to EBV (infectious mononucleosis), developed in collaboration with Jonas Banefelt […]
What’s it really like to be a project Leader at Quantify?
We asked our colleague Hannah Norman, Senior Project Leader in Market Access & HTA to share her experience.
💡What do project Leaders in Nordic Market Access and HTA actually do? “We help pharmaceutical companies bring life-saving and innovative medicines to market. The projects we manage range from small-scale assignments — such as a landscape analysis within a therapeutic area in one Nordic country, or gathering inputs for a health economic […]